Influenza Vaccines Sales Grow 13% in 2013, Top 3 Billion: Kalorama Information Report
New York, NY (PRWEB) May 12, 2014 -- The 2013 influenza season was the first in which quadrivalent influenza vaccines with an extra B strain were available in the U.S. According to Kalorama Information’s new report, “Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments,” this is one of the factors that helped revenues for flu vaccine makers last year. The healthcare market research publisher estimated that in 2013, influenza vaccines generated $3.1 billion in revenues, up from 2.8 billion in 2012.
The increase is significant according to Kalorama because there had been a large decrease in the influenza vaccine market in 2011. Vaccines sales in that year dropped 30%. Now Kalorama sees double-digit revenue growth for the remainder of the decade.
“We are back to 2008 market levels,” said Bruce Carlson, Publisher of Kalorama information. “Sales in this segment had been excessively strong, over six billion dollars in 2010 due to government stockpiling – and perhaps over-purchasing – of avian and swine flu. The market paid for that last two years, but it’s at normal levels now.”
New Products are part of the reason for the increase, according to Kalorama’s report. Until 2013, seasonal influenza vaccines included only one B strain. However, influenza B has been a common cause of flu-related morbidity and mortality as it is associated with pneumonia and other respiratory illnesses, nervous system disease, muscle pain and inflammation, and other complications. Almost half of influenza-associated deaths in children under 18 years of age are due to influenza B and epidemics of influenza B occur every two to four years in all age groups. New products include MedImmune’s Flumist Quadrivalent live attenuated influenza vaccine (LAIV4); Sanofi Pasteur’s Fluzone Quadrivalent inactivated influenza vaccine (IIV4); GlaxoSmithKline’s Fluarix IIV4; Novarti’s Flucelvax, a trivalent cell culture-based inactivated influenza vaccine; and Protein Sciences’ FluBlok, a recombinant hemagglutinin vaccine.
A stronger early flu season and increased awareness of the dangers of influenza helped boost sales, according to Kalorama. Vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, despite various vaccination campaigns and promotional efforts, immunization rates for these diseases continue to be low in the elderly population. In the U.S., for example, the Centers for Disease Control (CDC) has found that Influenza is responsible for 20,000 to 40,000 deaths annually, and up to 50,000 deaths and an estimated 200,000 excess hospitalizations at a cost of $750 million to $1 billion during epidemic years. Kalorama believes awareness of these costs on a personal and institutional level has driven sales to normal levels.
The report covers other categories of vaccines and makes forecasts about the future. Kalorama Information’s new report, “Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments,” can be found at: http://www.marketresearch.com/Kalorama-Information-v767/Vaccines-Key-Players-Trends-Pediatric-8120410/
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at http://www.kaloramainformation.com.
Bruce Carlson, Kalorama Information, http://www.KaloramaInformation.com, 212 807 2622, [email protected]
Share this article